Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Diagnostics and laboratory products / Clinical consumables and general diagnostics / Molecular and specialised-testing pre-analytical consumables

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Molecular and specialised-testing pre-analytical consumables

Consumables tied to molecular, microbiology and specialised testing workflows: swab and transport media, viral transport tubes, lysis/extraction accessories, PCR tube strips, plates and pipette consumables used by laboratories and testing sites running molecular panels. Excludes assay kits, reagents and instruments.

Market size
—
Not sized yet
Growth
—
CAGR
Attractiveness
75 /100
for B2B sellers
Evidence
not sized
1 source · no estimate
Level
Niche
Segmented by
Customer type
Buyers
Hospitals, reference laboratories and specialised molecular testing sites
Buying centre
Molecular diagnostics lab manager with procurement and (for molecular platforms) the instrument vendor's account team; centralised contracting for larger networks
Buying triggers
  • Rapid adoption of molecular panels noted as a North American growth driver
  • Respiratory and syndromic panel testing volumes
  • Automation of extraction and PCR workflows
  • Shift of assays from send-out to in-house molecular platforms
Pains
  • Proprietary consumable formats tied to instrument platforms
  • High consumable cost per molecular test limiting panel breadth
  • Cold-chain and transport-media integrity for molecular specimens
  • Supply allocation risk during demand spikes
Scores (1–5)
Pain intensity4
Purchasing power3
Reachability3
Growth5

How this was sized

Not sized yet

Bottom-up: worldwide laboratory diagnostics 2025 = USD 110.85bn [8]. Immunodiagnostics was 28.2% of that market in 2025 [8], implying a non-immunodiagnostics balance of about USD 79.6bn (110.85 x 71.8%). Applying a stated 4-7% consumables share to that non-immunodiagnostics pool gives roughly USD 3.2-5.6bn, i.e. USD 3,200-5,600m. Arithmetic: 110.85 x 0.718 = 79.59bn; x 4-7% = 3.2-5.6bn. Confidence Low: the 4-7% share is an assumption; the residual mixes molecular, chemistry, microbiology and other technologies, and the source does not size molecular diagnostics separately.

Sources

Alongside it in Clinical consumables and general diagnostics

// Sell into Molecular and specialised-testing pre-analytical consumables

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.